Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Use of cyclic depsipeptides to inhibit kallikrein 7

a technology of kallikrein and cyclic depsipeptides, which is applied in the direction of endopeptidase, peptide/protein ingredients, peptide sources, etc., can solve the problems of hk7 overactivation, disturbance of lamellar membrane architecture, and uncontrolled activation of proinflammatory cytokin

Inactive Publication Date: 2013-07-04
DR PY INST LLC +1
View PDF2 Cites 5 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Benefits of technology

The present invention is about certain compounds called cyclic depsipeptides, or derivatives of them, that can be used as a medication to treat diseases that are influenced by an enzyme called kallikrein 7. These compounds are particularly effective in treating Netherton's syndrome, prurigo nodularis, pustular psioriasis, and ovarian cancer.

Problems solved by technology

This might lead to an uncontrolled degradation of corneodesmosomes resulting in a miss-regulated desquamation, an enhanced degradation of lipid processing enzymes resulting in a disturbed lamellar membrane architecture or an uncontrolled activation of the proinflammatory cytokine IL-1β.
Uncontrolled activity of such an activating enzyme might result in an overactivation of hK7.

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Use of cyclic depsipeptides to inhibit kallikrein 7
  • Use of cyclic depsipeptides to inhibit kallikrein 7
  • Use of cyclic depsipeptides to inhibit kallikrein 7

Examples

Experimental program
Comparison scheme
Effect test

example 1

Production of the Compounds of Formula (II)-(VII)

Strain:

[0100]The Chondromyces crocatus strain was isolated from an environmental sample, rotten wood of a walnut tree, in our laboratories.

[0101]The strain has been unambiguously identified as a Chondromyces crocatus based on the morphology of the fruiting bodies as well as on the partial sequence of the 16S-RNA gene. C. crocatus was assigned to biological risk group 1 by the DSMZ (DSMZ (2007)).

[0102]Chondromyces is a genus in the family Polyangiaceae, which belongs to the order Myxococcales within the Delta-proteobacteria. Bacteria of the order Myxococcales, also called myxobacteria, are gram-negative rod-shaped bacteria with two characteristics distinguishing them from most other bacteria. They swarm on solid surfaces using an active gliding mechanism and aggregate to form fruiting bodies upon starvation (Kaiser (2003)).

[0103]The Chondromyces crocatus strain of the invention has been deposited at the DSMZ under the accession number ...

example 2

Production of Compound of Formula (VIII, IX, X)

Strain:

[0122]The Chondromyces robustus strain was isolated from a dung sample. The Chondromyces robustus strain of the invention has been identified as a Chondromyces robustus based on the morphology of the fruiting bodies as well as on the partial sequence of the 16S-RNA gene. C. robustus was assigned to biological risk group 1 by the DSMZ (DSMZ (2007)). Chondromyces is a genus in the family Polyangiaceae, which belongs to the order Myxococcales within the Delta-proteobacteria. Bacteria of the order Myxococcales, also called myxobacteria, are gram-negative rod-shaped bacteria with two characteristics distinguishing them from most other bacteria. They swarm on solid surfaces using an active gliding mechanism and aggregate to form fruiting bodies upon starvation (Kaiser (2003)).

[0123]The Chondromyces robustus strain of the invention has been deposited at the DSMZ under the accession number 19330.

Cultivation:

[0124]100 L fermentor cultures...

example 3

Biological Activity

[0137]The compounds of the present invention, e.g. including a compound of formula II-X, exhibit pharmacological activity and are therefore useful as pharmaceuticals. E.g., the compounds of the present invention are found to inhibit Kallikrein-7 activity.

[0138]Compounds of the present invention have IC50 values between 1 nM and 10 μM as determined in the following assay:

Materials and Buffers

[0139]The fluorescence-quenched substrate Ac-Glu-Asp(EDANS)-Lys-Pro-Ile-Leu-PhêArg-Leu-Gly-Lys(DABCYL)-Glu-NH2 (where ̂ indicates the scissile bond, identified by MS analysis) is purchased from Biosyntan (Berlin, Germany) and kept as a 5 mM stock solution in DMSO at −20° C. All other chemicals are of analytical grade.

[0140]Enzymatic reactions are conducted in 50 mM sodium citrate buffer at pH 5.6 containing 150 mM NaCl and 0.05% (w / v) CHAPS.

[0141]All protein and peptide containing solutions are handled in siliconized tubes (Life Systems Design, Merenschwand, Switzerland). The ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The present application relate to cyclic depsipeptides, or derivatives thereof, having the formula (I), and uses thereof, e.g. as inhibitors of kallikrein 7.

Description

FIELD OF THE INVENTION[0001]The present invention relates to cyclic depsipeptides, or a derivatives thereof.BACKGROUND OF THE INVENTION[0002]Kallikrein 7 is a S1 serine protease of the kallikrein gene family displaying a chymotrypsin like activity. Human kallikrein 7 (hK7, KLK7 or stratum corneum chymotryptic enzyme (SCCE), Swissprot P49862) plays an important role in skin physiology (1, 2, 3). It is mainly expressed in the skin and has been reported to play an important role in skin physiology. hK7 is involved in the degradation of the intercellular cohesive structures in cornified squamous epithelia in the process of desquamation. The desquamation process is well regulated and delicately balanced with the de novo production of corneocytes to maintain a constant thickness of the stratum corneum, the outermost layer of the skin critically involved in skin barrier function. In this regard, hK7 is reported to be able to cleave the corneodesmosomal proteins corneodesmosin and desmocoll...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(United States)
IPC IPC(8): A61K38/15
CPCA61K38/00A61K38/15C07K14/811C07K7/06A61P17/00A61P17/04A61P17/06A61P35/00A61P43/00
Inventor KRASTEL, PHILIPPLIECHTY, BRIGITTA-MARIASCHMITT, ESTHERSCHREINER, ERWIN PAUL
Owner DR PY INST LLC
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com